4
Participants
Start Date
October 31, 2000
Primary Completion Date
April 30, 2002
Study Completion Date
April 30, 2002
temozolomide
Administered in a fasting state, once a day for 6 weeks followed by 4 weeks of rest. Cycles may be repeated every 10 weeks until patients have evidence of progressive disease, intolerable toxicity or unwillingness to continue therapy. Daily dose: 75mg/m2.
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles
Collaborators (1)
Schering-Plough
INDUSTRY
Jonsson Comprehensive Cancer Center
OTHER